Conference Reports for NATAP

Back

AASLD The Liver Meeting Boston MA November 2016     Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) - (10/21/16)   Summary for AASLD 2016 for Hepatitis C - New HCV two and three drug regimens on their way: what do they promise? And what do clinicians need to look out for under DAA combination therapy and beyond SVR? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/13/16)   Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the CheckMate 040 Study - (07/22/17)   SVR12 rates under DAA-based HCV therapy from the National German Cohort Study: Does HIV co-infection impair the response to DAA combination therapy? - (12/15/16)   A Phase 2 Study of BMS-986036 (PegylatedFGF21) in Obese Adults with Type 2 Diabetes and a High Prevalence of Fatty Liver - (12/15/16)   Retreatment with Sofosbuvir + Grazoprevir + Elbasvir + Ribavirin of Patients with Hepatitis C Virus Genotype 1 or 4 with RASs at Failure of a Sofosbuvir + Ledipasvir or + Declatasvir or + Simeprevir Regimen - (12/15/16)   8 Weeks Treatment Under Real Life Conditions with Ledipasvir/Sofosbuvir in HIV Co-Infected Treatment-Naïve HCV Genotype 1 Infected Patients with Similar Results to Mono-Infected HCV Patients: data from the German Hepatitis C-Registry (DHC-R) - (12/15/16)   Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (> 70 yrs): Results from the German Hepatitis C-Registry (DHC-R) - (12/15/16)   Treatment of HCV in the Department of Corrections in the Era of oral Direct Acting Antivirals - (12/15/16)   Four Weeks Treatment of Injection Drug Users with Chronic Hepatitis C - (12/15/16)   Risk of Incident Liver Cancer Following HCV Treatment With Sofosbuvir-Containing Regimens - (12/15/16)   Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis - (12/15/16)   Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers (CpAMs) - (12/08/16)   Are risk factors still relevant for HCV treatment with directly-acting agents against HCV in HIV-HCV-coinfection? - Results from the German hepatitis C cohort (GECCO) - (12/08/16)   High Cure Rates after Directly Acting Antivirals in Patients with Chronic Hepatitis C and Psychiatric Disorders - (12/08/16)   Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection - (12/07/16)   Exploring Combination Therapy for Curing HBV - Preclinical Combo Studies with Capsid Inhibitor AB-423 and siRNA Agent ARB-1740 - (12/07/16)   The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies - (12/07/16)   Sofosbuvir + Ribavirin for 12 or 24 Weeks Is Safe and Effective in Adolescents With Genotype 2 or Genotype 3 Chronic Hepatitis C Infection - (12/07/16)   HCC Risk/DAAs - Long Term Followup SVR / SVR Durability - (12/06/16)   Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A review of Spontaneous Post-Marketing Cases - (12/06/16)   Efficacy and safety of DAA-based oral therapy in a large cohort of HCV patientstreated in clinical practice in Italy and monitored by the NAVIGATORE web-platform - (12/05/16)   Treatment outcomes for hepatitis C genotype 1 infection with direct acting antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R) - (12/01/16)   EFFECTIVENESS OF DACLATASVIR PLUS SOFOSBUVIR IN HCV-GT3 PATIENTS RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (12/01/16)   Are risk factors still relevant for HCV treatment with directly-acting agents against HCV in HIV-HCV-coinfection? Results from the German hepatitis C cohort (GECCO) - (12/01/16)   A Prospective Study of The Association of Body Morphometry With Hepatic Steatosis and Fibrosis in HIV-HCV Coinfected Patients - (11/30/16)   Sofosbuvir-Based Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies - (11/30/16)   Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects:Madrid Coinfection Registry (Madrid-CoRE) Findings - (11/30/16)   HCV at AASLD / New HCV Drugs / New NASH Drugs - (11/30/16)   HCC Risk/DAAs - Long Term Followup SVR / SVR Durability - (11/30/16)   Sofosbuvir-Based Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies - (11/30/16)   Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients With Mild or Moderate Renal Impairment - (11/30/16)   DIAGNOSTIC PATTERN AND DISEASE ACTIVITY ARE RELATED TO DISEASE PROGRESSION AND REGRESSION IN NONALCOHOLIC FATTY LIVER DISEASE - (11/29/16)   Evaluation of the Safety and Pharmacokinetics of the Oral, Nonsteroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers - (11/29/16)   Ledipasvir/Sofosbuvir + Ribavirin for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-World Dataset - (11/29/16)   Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List - (11/29/16)   Predictors of Improvement in Glomerular Filtration Rate Among Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin - (11/29/16)   Improved Hepatic Profile in Hepatitis C Virus (HCV) Genotype (GT) 4-Infected Egyptian Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-II) - (11/29/16)   Regulus Expands Clinical Trial Collaboration with GSK ....."potential single-visit cure" - (11/29/16)   A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients - (11/29/16)   Poor Adherence to Hepatocellular Carcinoma (HCC) Surveillance in a U.S. Cohort of 2,917 Patients with Chronic Hepatitis C (CHC) and Cirrhosis - (11/28/16)   Poor Adherence to Hepatocellular Carcinoma (HCC) Surveillance in a U.S. Cohort of 2,917 Patients with Chronic Hepatitis C (CHC) and Cirrhosis - (11/28/16)   Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects: Madrid Coinfection Registry (Madrid-CoRE) Findings - (11/28/16)   GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Patients With Genotype 1a Chronic Hepatitis C Virus Infection Without Cirrhosis - (11/28/16)   Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, and Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Antiviral Regimens for Hepatitis C In 17,847 Patients in the Veterans Affairs National Healthcare System - (11/28/16)   Impact of all-oral antiviral therapy on portal pressure and hemodynamics on HCV-infected cirrhotic patients. - (11/28/16)   Predictors of Sustained Virologic Response in 21,242 Genotype 1 Patients Treated with Ledipasvir/Sofosbuvir±Ribavirin or Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in Routine Medical Practice - (11/28/16)   Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Results - (11/28/16)   Hepatitis B Reactivation in Patients Receiving Interferon-Free Direct Acting Antiviral Agents for Chronic Hepatitis C Virus Infection - (11/23/16)   Predictors of HBeAg Loss in HBeAg-Positive Patients With Chronic Hepatitis B During Treatment With TAF or TDF - (11/22/16)   Correlation of Early Biochemical and Virologic Responses During Oral Antiviral Therapy for Chronic Hepatitis B - (11/22/16)   Features of the Metabolic Syndrome Are Associated With Lack of Serum ALT Normalization During Therapy for Chronic Hepatitis B - (11/22/16)   Characterization of Changes in FibroTest Values During Treatment With TAF or TDF in Patients With CHB - (11/22/16)   Characterization of Host, Viral, and Treatment-Related Factors Associated With Antiviral Efficacy of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate - (11/22/16)   No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients With Chronic Hepatitis B - (11/22/16)   HBV Genotype Is Associated With Early (Week 12) Virologic Response During Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Therapy in Patients With Chronic Hepatitis B - (11/22/16)   LUNAR™-HBV, a UNA Oligomer Combination for the Treatment of Chronic Hepatitis B Virus Infection - (11/22/16)   Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (11/22/16)   Improved Renal Laboratory Parameters in CHB Patients Treated With TAF Compared With TDF - (11/22/16)   HEPATITIS B (HBV) REACTIVATION DURING ANTI-HEPATITIS C (HCV) THERAPY WITH INTERFERON (IFN)-FREE REGIMENS: A PROSPECTIVE STUDY - (11/22/16)   Comparison of Markers of Bone Turnover Demonstrates Less Changes in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (11/22/16)   Reduced Changes in Bone Mineral Density in Chronic HBV (CHB) Patients Receiving Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) - (11/22/16)   TLR-7 agonist GS-9620 can improve HBV-specific T cell and NK cell responses in nucleos(t)ide suppressed patients with chronic hepatitis B - (11/22/16)   Safety, tolerability and pharmacokinetics of JNJ-56136379, a novel HBV capsid assembly modulator, in healthy subjects - (11/22/16)   Capsid assembly modulator JNJ-56136379 prevents de novo infection of primary human hepatocytes with hepatitis B virus - (11/22/16)   Ledipasvir/Sofosbuvir in Egyptian Patients With Chronic Genotype 4 HCV Infection - (11/21/16)   Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium - (11/21/16)   Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world - (11/21/16)   Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network - (11/21/16)   Assessment of risk of acute kidney injury associated with exposure to sofosbuvir-containing HCV treatment regimens and HCV infection - (11/21/16)   Towards a Single Treatment Cure for HCV: Reformulation of the Pangenotypic NS5B NNI GSK2878175 as a Long Acting Parenteral (LAP) - (11/21/16)   HCV Screening and Infection awareness in a cohort of HIV infected & Uninfected and Marginally Housed Women in San Francisco..... - (11/21/16)   The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US - (11/21/16)   Real World Effectiveness of Ledipasvir/Sofosbuvir in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts - (11/21/16)   GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial - (11/21/16)   EIGHT WEEKS TREATMENT DURATION WITH LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IS EFFECTIVE FOR APPROPRIATELY SELECTED PATIENTS WITH GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION: AN ANALYSIS OF MULTIPLE REAL WORLD COHORTS TOTALING >6,500 PATIENTS - (11/21/16)   ELEVATED HCV REINFECTION INCIDENCE AFTER SUCCESSFUL TREATMENT AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO - (11/21/16)   Impact of Drug Use and Opioid Substitution Therapy on Hepatitis C Reinfection: The BC Hepatitis Testers Cohort - (11/21/16)   New HCV Drugs at AASLD - (11/21/16)   The impact of sustained virological response to HCV infection on long term risk of hepatocellular carcinoma: The BC Hepatitis Testers Cohort - (11/17/16)   Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients With Chronic HCV Infection and HIV/HCV Coinfection - in Russia - (11/17/16)   INTERIM ANALYSIS OF A 3-YEAR FOLLOW-UP STUDY OF NS5A AND NS3 RESISTANCE-ASSOCIATED VARIANTS AFTER TREATMENT WITH GRAZOPREVIR-CONTAINING REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION - (11/17/16)   Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients With Chronic HCV Infection and HIV/HCV Coinfection - in Russia - (11/17/16)   "Incidence and pattern of "de novo" hepatocellular carcinoma in HCV patients treated with oral DAAs" - (11/17/16)   ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ± RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY - (11/17/16)   High Rates of Medical and Psychiatric Comorbidities in HIV/HCV-Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials - Harvoni / Epclusa - (11/17/16)   QUARTZ II-III: Final Efficacy and Safety Results in Patients With HCV Genotype 2 or 3 Infection - Abbvie 2D + Sofosbuvir in Gt3 [12 weeks] & Gt2 (6, 8 weeks) - treatment experienced & naive - (11/17/16)   ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered With Ribavirin in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis - (11/17/16)   Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin: First Interim Safety and Efficacy Results From TOPAZ-I - (11/17/16)   An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.... .49% had ongoing psych disorders - (11/17/16)   SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir [ABT493+ABT530] Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration - (11/17/16)   Six weeks of sofosbuvir/ledipasvir treatment of acute hepatitis C virus genotype 1 mono-infection: Final results of The German HepNet Acute HCV IV Study......55% were sexual transmission including 5 MSM - (11/17/16)   ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study - (11/17/16)   Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - (11/17/16)   Healthy Eating Patterns - Eat Your Way to a Healthy Liver / NASH-Fatty Liver - (11/16/16)   RUBY-II: Efficacy and Safety of a Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir Regimen in Patients With Severe Renal Impairment or End-Stage Renal Disease and HCV Genotype 1a or 4 Infection - (11/16/16)   RG-101 + DAAs - New Combination Therapy Could Cure Hepatitis C With Only 4 Weeks of Treatment - (11/16/16)   Impact of treatment induced vs. spontaneous HCV clearance on the long term risk of hepatocellular carcinoma: BC Hepatitis Testers Cohort - (11/16/16)   Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the CheckMate 040 Study - (11/16/16)   SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration - (11/16/16)   The Safety and Tolerability of Sofosbuvir/Velpatasvir With Weight-Based Ribavirin in Patients With Child-Pugh Turcotte Class B Cirrhosis in the ASTRAL-4 Study - (11/15/16)   RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection With Severe Renal Impairment or End-Stage Renal Disease - (11/15/16)   RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection With Severe Renal Impairment or End-Stage Renal Disease - (11/15/16)   A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study - (11/15/16)   A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study - (11/15/16)   ENDURANCE-1: A Phase 3 Evaluation of the Efficacy and Safety of 8- versus 12-week Treatment with Glecaprevir/Pibrentasvir (formerly ABT-493/ABT-530) in HCV Genotype 1 Infected Patients with or without HIV-1 Co-infection and without Cirrhosis - (11/15/16)   EXPEDITION-4: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH RENAL IMPAIRMENT AND CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION - (11/15/16)   Distinct evolutionary pathways of NS5A inhibitor resistance in patients with genotype 1a versus 1b infection during monotherapy with MK-8742 (Elbasvir) - (11/15/16)   Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients With Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study - (11/15/16)   Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) - (11/15/16)   Long-term follow-up of patients with chronic HCV infection & treated with daclatasvir-based regimens in phase 2 and 3 studies - (11/15/16)   Integrated Analysis of Sofosbuvir +Ribavirin, Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir for the Treatment of Genotype 4 Chronic HCV Infection - (11/15/16)   Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the Hepatitis C Virus (HCV) Subgenomic Replicon System - (11/15/16)   Pharmacokinetics (PK), safety and tolerability of the 2-and 3-direct acting antiviral (DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered once-daily (QD) in healthy volunteers (HVs) - (11/15/16)   Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients With Mild or Moderate Renal Impairment - (11/14/16)   ENDURANCE-4: Efficacy and Safety of Glecaprevir/Pibrentasvir (Formerly ABT-493/ABT-530) Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection - (11/14/16)   SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS - (11/14/16)   High Sustained Virologic Response Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2) - (11/14/16)   A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1-6 HCV Infection: The POLARIS-4 Study - (11/14/16)   Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & -2) - (11/14/16)   EFFICACY AND SAFETY OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NAïVE PATIENTS WITH CHRONIC HCV GT 1, GT 4 AND GT 6 INFECTION (C-CORAL): A PHASE III RANDOMIZED MULTINATIONAL CLINICAL TRIAL - (11/14/16)   ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ± RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY - (11/14/16)   ENDURANCE-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Hepatitis C Virus Genotype 2-infected Patients without Cirrhosis: a Randomized, Double-Blind, Placebo-Controlled Study - (11/14/16)   Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to <12 Years Old - (11/14/16)   Long-term Follow-up of Patients With Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment With Sofosbuvir-Based Regimens - (11/14/16)   Real World Effectiveness of Ledipasvir/Sofosbuvir in Patients Coinfected With HCV and HIV-1:A Comparative Analysis of Clinical Trials with Four Real World Cohorts - (11/14/16)   C-EDGE CO-STAR: Interim Results From the 3-year Follow-up Trial on Risk Factors and Rate of Reinfection in Patients on Opiate Agonist Therapy Previously Treated With Elbasvir/Grazoprevir for 12 Weeks - (11/14/16)   Integrated Resistance Analyses of HCV-Infected Patients Treated With Sofosbuvir, Velpatasvir, and Voxilaprevir for 8 and 12 Weeks From Phase 2 Studies - (11/14/16)   Final Results From Phase 3 Portion in Phase 2/3 Study of Elbasvir/Grazoprevir in Hepatitis C Genotype 1-Infected Japanese Patients - (11/14/16)   High Efficacy in Patients With Chronic Hepatitis C Virus (HCV) Genotype 1b Infection Treated with Elbasvir/Grazoprevir for 12 Weeks: An Integrated Analysis - (11/14/16)   Elbasvir/Grazoprevir Does Not Worsen Renal Function in Patients With Hepatitis C Virus Infection and Pre-existing Renal Disease - (11/14/16)   Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Elbasvir/Grazoprevir in Hepatitis C Genotype 1-Infected Japanese Patients - (11/14/16)   Concomitant Proton Pump Inhibitor Use Does Not Reduce the Efficacy of Elbasvir/Grazoprevir - (11/14/16)   Chronic Hepatitis C Virus Infection and Cancer Risks: A Population-Based Cohort Study - (11/14/16)   The Impact of Hepatitis C Viral Cure on Progression of Renal Disease - (11/14/16)   Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® - (11/14/16)